Treatment at Relapse for Synovial Sarcoma of Children, Adolescents and Young Adults: From the State of Art to Future Clinical Perspectives

Andrea Ferrari; Pablo Berlanga; Susanne Andrea Gatz; Reineke A. Schoot; Max M. van Noesel; Shushan Hovsepyan; Stefano Chiaravalli; Luca Bergamaschi; Veronique Minard-Colin; Nadege Corradini; Rita Alaggio; Patrizia Gasparini; Bernadette Brennan; Michela Casanova; Sandro Pasquali; Daniel Orbach

doi:10.2147/CMAR.S404371

Treatment at Relapse for Synovial Sarcoma of Children, Adolescents and Young Adults: From the State of Art to Future Clinical Perspectives

Andrea Ferrari^*, Pablo Berlanga, Susanne Andrea Gatz, Reineke A. Schoot, Max M. van Noesel, Shushan Hovsepyan, Stefano Chiaravalli, Luca Bergamaschi, Veronique Minard-Colin, Nadege Corradini, Rita Alaggio, Patrizia Gasparini, Bernadette Brennan, Michela Casanova, Sandro Pasquali, Daniel Orbach

^*Corresponding author for this work

Cancer and Genomic Sciences

Research output: Contribution to journal › Review article › peer-review

48 Downloads (Pure)

Abstract

While the overall prognosis is generally quite satisfactory in children, adolescents and young adults with localised synovial sarcoma at first diagnosis, the outcome remains poor for patients after relapse. Conversely to the front-line standardised treatment options, patients with relapse generally have an individualised approach and to date, there is still a lack of consensus regarding standard treatment approaches. Studies on relapsed synovial sarcoma were able to identify some prognostic variables that influence post-relapse survival, in order to plan risk-adapted salvage protocols. Treatment proposals must consider previous first-line treatments, potential toxicities, and the possibility of achieving an adequate local treatment by new surgery and/or re-irradiation. Effective second-line drug therapies are urgently needed. Notably, experimental treatments such as adoptive engineered TCR-T cell immunotherapy seem promising in adults and are currently under validation also in paediatric patients.

Original language	English
Pages (from-to)	1183-1196
Number of pages	14
Journal	Cancer Management and Research
Volume	15
DOIs	https://doi.org/10.2147/CMAR.S404371
Publication status	Published - 27 Oct 2023

Bibliographical note

Funding Information:
Dr Pablo Berlanga received grants for Drug supply for a trial from BAYER; an advisor for EUSA Pharma, outside the submitted work. Dr Susanne Andrea Gatz reports sponsorship of clinical trial from AstraZeneca, grants from BAYER, advisory board participation and received consultant fees from EMD Serono/MERCK KGaA, consultant fees for being reviewer on joint French Cancer Institute/AMGEN call from AMGEN, sponsorship of clinical trial from GSK, outside the submitted work. Dr Daniel Orbach reports grants from Bayer Inc., outside the submitted work. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publisher Copyright:
© 2023 Ferrari et al.

Keywords

children
new agents
relapse
second line therapy
surgery
synovial sarcoma
TCR-T cell therapy

ASJC Scopus subject areas

Oncology

Access to Document

10.2147/CMAR.S404371Licence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

FerrariA2023TreatmentFinal published version, 674 KBLicence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

Cite this

Ferrari, A., Berlanga, P., Gatz, S. A., Schoot, R. A., van Noesel, M. M., Hovsepyan, S., Chiaravalli, S., Bergamaschi, L., Minard-Colin, V., Corradini, N., Alaggio, R., Gasparini, P., Brennan, B., Casanova, M., Pasquali, S., & Orbach, D. (2023). Treatment at Relapse for Synovial Sarcoma of Children, Adolescents and Young Adults: From the State of Art to Future Clinical Perspectives. Cancer Management and Research, 15, 1183-1196. https://doi.org/10.2147/CMAR.S404371

@article{424b6f463eca454db74fe2df93589b13,

title = "Treatment at Relapse for Synovial Sarcoma of Children, Adolescents and Young Adults: From the State of Art to Future Clinical Perspectives",

abstract = "While the overall prognosis is generally quite satisfactory in children, adolescents and young adults with localised synovial sarcoma at first diagnosis, the outcome remains poor for patients after relapse. Conversely to the front-line standardised treatment options, patients with relapse generally have an individualised approach and to date, there is still a lack of consensus regarding standard treatment approaches. Studies on relapsed synovial sarcoma were able to identify some prognostic variables that influence post-relapse survival, in order to plan risk-adapted salvage protocols. Treatment proposals must consider previous first-line treatments, potential toxicities, and the possibility of achieving an adequate local treatment by new surgery and/or re-irradiation. Effective second-line drug therapies are urgently needed. Notably, experimental treatments such as adoptive engineered TCR-T cell immunotherapy seem promising in adults and are currently under validation also in paediatric patients.",

keywords = "children, new agents, relapse, second line therapy, surgery, synovial sarcoma, TCR-T cell therapy",

author = "Andrea Ferrari and Pablo Berlanga and Gatz, {Susanne Andrea} and Schoot, {Reineke A.} and {van Noesel}, {Max M.} and Shushan Hovsepyan and Stefano Chiaravalli and Luca Bergamaschi and Veronique Minard-Colin and Nadege Corradini and Rita Alaggio and Patrizia Gasparini and Bernadette Brennan and Michela Casanova and Sandro Pasquali and Daniel Orbach",

note = "Funding Information: Dr Pablo Berlanga received grants for Drug supply for a trial from BAYER; an advisor for EUSA Pharma, outside the submitted work. Dr Susanne Andrea Gatz reports sponsorship of clinical trial from AstraZeneca, grants from BAYER, advisory board participation and received consultant fees from EMD Serono/MERCK KGaA, consultant fees for being reviewer on joint French Cancer Institute/AMGEN call from AMGEN, sponsorship of clinical trial from GSK, outside the submitted work. Dr Daniel Orbach reports grants from Bayer Inc., outside the submitted work. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Publisher Copyright: {\textcopyright} 2023 Ferrari et al.",

year = "2023",

month = oct,

day = "27",

doi = "10.2147/CMAR.S404371",

language = "English",

volume = "15",

pages = "1183--1196",

journal = "Cancer Management and Research",

issn = "1179-1322",

publisher = "Dove Medical Press Ltd.",

}

Ferrari, A, Berlanga, P, Gatz, SA, Schoot, RA, van Noesel, MM, Hovsepyan, S, Chiaravalli, S, Bergamaschi, L, Minard-Colin, V, Corradini, N, Alaggio, R, Gasparini, P, Brennan, B, Casanova, M, Pasquali, S & Orbach, D 2023, 'Treatment at Relapse for Synovial Sarcoma of Children, Adolescents and Young Adults: From the State of Art to Future Clinical Perspectives', Cancer Management and Research, vol. 15, pp. 1183-1196. https://doi.org/10.2147/CMAR.S404371

TY - JOUR

T1 - Treatment at Relapse for Synovial Sarcoma of Children, Adolescents and Young Adults

T2 - From the State of Art to Future Clinical Perspectives

AU - Ferrari, Andrea

AU - Berlanga, Pablo

AU - Gatz, Susanne Andrea

AU - Schoot, Reineke A.

AU - van Noesel, Max M.

AU - Hovsepyan, Shushan

AU - Chiaravalli, Stefano

AU - Bergamaschi, Luca

AU - Minard-Colin, Veronique

AU - Corradini, Nadege

AU - Alaggio, Rita

AU - Gasparini, Patrizia

AU - Brennan, Bernadette

AU - Casanova, Michela

AU - Pasquali, Sandro

AU - Orbach, Daniel

N1 - Funding Information: Dr Pablo Berlanga received grants for Drug supply for a trial from BAYER; an advisor for EUSA Pharma, outside the submitted work. Dr Susanne Andrea Gatz reports sponsorship of clinical trial from AstraZeneca, grants from BAYER, advisory board participation and received consultant fees from EMD Serono/MERCK KGaA, consultant fees for being reviewer on joint French Cancer Institute/AMGEN call from AMGEN, sponsorship of clinical trial from GSK, outside the submitted work. Dr Daniel Orbach reports grants from Bayer Inc., outside the submitted work. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Publisher Copyright: © 2023 Ferrari et al.

PY - 2023/10/27

Y1 - 2023/10/27

N2 - While the overall prognosis is generally quite satisfactory in children, adolescents and young adults with localised synovial sarcoma at first diagnosis, the outcome remains poor for patients after relapse. Conversely to the front-line standardised treatment options, patients with relapse generally have an individualised approach and to date, there is still a lack of consensus regarding standard treatment approaches. Studies on relapsed synovial sarcoma were able to identify some prognostic variables that influence post-relapse survival, in order to plan risk-adapted salvage protocols. Treatment proposals must consider previous first-line treatments, potential toxicities, and the possibility of achieving an adequate local treatment by new surgery and/or re-irradiation. Effective second-line drug therapies are urgently needed. Notably, experimental treatments such as adoptive engineered TCR-T cell immunotherapy seem promising in adults and are currently under validation also in paediatric patients.

AB - While the overall prognosis is generally quite satisfactory in children, adolescents and young adults with localised synovial sarcoma at first diagnosis, the outcome remains poor for patients after relapse. Conversely to the front-line standardised treatment options, patients with relapse generally have an individualised approach and to date, there is still a lack of consensus regarding standard treatment approaches. Studies on relapsed synovial sarcoma were able to identify some prognostic variables that influence post-relapse survival, in order to plan risk-adapted salvage protocols. Treatment proposals must consider previous first-line treatments, potential toxicities, and the possibility of achieving an adequate local treatment by new surgery and/or re-irradiation. Effective second-line drug therapies are urgently needed. Notably, experimental treatments such as adoptive engineered TCR-T cell immunotherapy seem promising in adults and are currently under validation also in paediatric patients.

KW - children

KW - new agents

KW - relapse

KW - second line therapy

KW - surgery

KW - synovial sarcoma

KW - TCR-T cell therapy

UR - http://www.scopus.com/inward/record.url?scp=85175097164&partnerID=8YFLogxK

U2 - 10.2147/CMAR.S404371

DO - 10.2147/CMAR.S404371

M3 - Review article

AN - SCOPUS:85175097164

SN - 1179-1322

VL - 15

SP - 1183

EP - 1196

JO - Cancer Management and Research

JF - Cancer Management and Research

ER -

Treatment at Relapse for Synovial Sarcoma of Children, Adolescents and Young Adults: From the State of Art to Future Clinical Perspectives

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this